Peripheral artery disease (PAD) is a condition characterized by arterial narrowing due to atherosclerosis. It affects more than 113 million people worldwide and is associated with elevated risks of cardiovascular events and mortality. It is mainly treated with percutaneous transluminal angioplasty (PTA), a minimally invasive endovascular procedure used to restore blood flow in obstructed lower limb arteries. While commercial drug-coated balloons (DCBs) reduce lesion failure compared to uncoated balloons (28.6% vs. 17.9%), they are also associated with high rates of thrombosis (3%–10%) and restenosis (20%–45%) within 6-12 months after below-the-knee intervention. These limitations are largely attributed to inefficient drug transfer and distribution to the vessel wall.